Source: DGNews  |  Posted 5 years ago

There was an error in the title of our DG Dispatch (May 4, 2006) based on a presentation at the American Association of Clinical Endocrinologists (AACE) annual meeting.

The title should have stated as follows:

Higher Risk Patients Benefit More After Conversion from Rosiglitazone to Pioglitazone

We apologise to the manufacturer for having published inaccurate information on their product.

We are committed to providing the most accurate, relevant and balanced information for physicians worldwide and have devoted considerable resources to ensuring this. We deeply regret this error.